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ABSTRACT 
 
HEPATITIS C AND RISK OF ADVERSE TREATMENT OUTCOMES AMONG PATIENTS 
WITH HIV AND MULTIDRUG-RESISTANT TUBERCULOSIS 
 
By 
 
AUNG AUNG 
 
July 19, 2018 
 
 
 
BACKGROUND 
Multidrug-resistant (MDR) tuberculosis (TB) is a public health emergency that causes 
substantial morbidity and mortality. Treatment of MDR-TB requires 9-24 months of second-line 
regimens, has poor success rates, and frequently results in harmful side effects. Hepatitis C virus 
(HCV) co-infection is a common comorbidity among patients with MDR-TB/HIV and 
contributes to acute and chronic liver conditions, potentially increasing the risk of hepatotoxicity 
and adverse treatment outcomes. The aim of this study was to estimate the association between 
HCV co-infection and adverse MDR-TB treatment outcomes among patients with MDR-TB and 
HIV. 
 
METHODS 
We conducted a retrospective cohort study among MDR-TB patients co-infected with HIV 
receiving clinical care from Médecins Sans Frontières (MSF) in Yangon, Myanmar during 2009-
2017. Eligible patients included adults aged ≥18 years who had final MDR-TB treatment 
outcome and HCV status documented. HCV status was determined by OraQuick® antibody test. 
Treatment outcome was classified as favorable (cured and treatment completed) or adverse 
(default, failed, died, not evaluated).  
 
RESULTS 
Among patients with MDR-TB and HIV (n=220), the overall treatment success rate was 65% 
(95%CI 59 – 71%) and 8% (95%CI 5-12%) had HCV. Co-infection with HCV was not 
significantly associated with adverse treatment outcome in unadjusted (OR 1.33, 95%CI 0.49 – 
3.65) or adjusted analyses (aOR 1.43, 95%CI 0.50 – 4.03).   
 
CONCLUSION 
Whether patients with HIV/HCV co-infection require altered MDR-TB treatment regimens 
remains an important gap in knowledge. Additional research is needed to determine the 
relationship between the extent of hepatotoxicity due to HCV co-infection, interaction with 
second-line TB medications, and risk of poor MDR-TB treatment outcomes among patients with 
and without HIV.  
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CHAPTER I 
INTROUDCTION  
1.1 Background 
The global ambition to end the tuberculosis (TB) epidemic is determined by the End-TB 
Strategy. This global target is set for 2035 when the End-TB goals state mortality rates should 
have a 95% reduction compared to 2015, and reduction of TB incidence rate <10 per 100,000 
population. To achieve the global End-TB targets, priority indicators are to reach TB treatment 
coverage and success rate to ⩾ 95% and to reduce case fatality ratio (CFR) to < 5%. Although 
some progress has been made in achieving global targets, key challenges like multidrug-resistant 
tuberculosis (MDR-TB) and lack of funding prohibit full realization of these End-TB goals 
(World Health Organization, 2014). 
In 2016 the global TB incidence was estimated at 10.4 million people and accounted for 
approximately 1.3 million deaths and an additional 0.4 million deaths among HIV-positive 
people. MDR-TB is a form of TB resistant to at least two of the most potent anti-TB drugs 
(rifampicin and isoniazid), and the 2016 MDR TB incidence was 490,000 (World Health 
Organization, 2017c). The global prevalence of hepatitis C virus (HCV) infection was 71 million 
people in 2015, and almost 400,000 die annually due to chronic HCV infection (World Health 
Organization, 2017b).  
Myanmar is included in 30 high burden countries (HBC) with overlapping TB, MDR-TB 
and HIV/TB epidemics (World Health Organization, 2015). In Myanmar, the overall incidence 
of MDR-TB and RR-TB was 13,000 (8,800 – 18,000) in 2016. Among them, only 1,497 
MDR/RR-TB cases were started on second-line treatment in 2014, and the success rate was 
estimated to have 80% (World Health Organization, 2017a). The rate of HCV was 2% among 
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healthy individuals, and 27% in patients with acute and chronic liver conditions in Myanmar in 
2001 (Nakai, Win, Oo, Arakawa, & Abe, 2001).  
Treatment of MDR-TB is available, but it requires substantially longer duration (9 – 24 
months) with more expensive second-line toxic drugs (Marks et al., 2014) and the treatment is 
less effective than the treatment of drug-sensitive TB (Micheletti, Kritski, & Braga, 2016). 
Moreover, there are multiple side-effects of MDR-TB treatment for patients ranging from self-
limiting reactions like arthralgia (aching or pain in the joints) and dermatological complications 
(Yang et al., 2017) to life-threatening toxicities such as nephrotoxicity, cardiotoxicity, and 
hepatotoxicity (Ramachandran & Swaminathan, 2015). HCV infection frequently results in 
chronic liver disease with causes persistent liver cell damage leading to cirrhosis and 
hepatocellular carcinoma. HCV co-infection is common among HIV patients (Platt et al., 2016), 
and TB patients. The triad of HCV, HIV, and TB promotes the additional risk of drug-induced 
liver injury during the TB treatment in HIV population (Kwon et al., 2007). Given the increased 
risk of MDR-TB treatment on hepatotoxicity, HCV co-infection may augment the risk of liver 
disease during the treatment, leading to a higher chance of adverse MDR-TB treatment 
outcomes. 
MDR-TB treatment success rates are not as favorable as drug-sensitive TB. According to 
MDR-TB outcome analysis by Falzon et al. (Falzon et al., 2015), the treatment outcome among 
23 high TB burden countries has a median success rate of 53% (IQR 40% - 70%). Many factors 
are associated with adverse treatment outcome particularly HIV co-infection (Farley et al., 2011) 
and chronic HCV co-infection (Kikvidze & Ikiashvili, 2014). Studies found that drug-induced 
hepatotoxicity in TB and MDR-TB treatment was associated with HCV co-infection (Lee et al., 
2016; Lomtadze et al., 2013). There were also other studies on MDR-TB treatment outcome 
11 
 
which suggested that mortality rate during TB treatment was higher among individuals living 
with HIV (Isaakidis et al., 2015). However, the impact of HCV infection on MDR-TB treatment 
outcomes in the context of HIV co-infection is still needed to elaborate. 
 
1.2 Gap and Purpose of Study  
Current knowledge on MDR-TB outcomes among patients with HCV and HIV infection 
is limited.  Improved knowledge regarding the role of HCV in adverse MDR-TB outcome in 
patients with HIV may inform future clinical HIV-TB guidelines including how to monitor side 
effects, and risk stratification. Mortality due to MDR-TB is high even with the proper treatment 
(Chung-Delgado, Guillen-Bravo, Revilla-Montag, & Bernabe-Ortiz, 2015; Gandhi et al., 2012). 
Even incremental improvements in MDR-TB treatment outcomes may substantially improve 
clinical care for high HIV/TB burden countries like Myanmar. Therefore, in the cohort of HIV 
patients with MDR-TB in Myanmar, the aims of our study are to  
1) Determine socioeconomic, clinical and laboratory characteristics associated with 
HCV infection; 
2) Determine the association between HCV comorbidity and adverse MDR-TB 
treatment outcomes.  
12 
 
CHAPTER II  
REVIEW OF LITERATURE 
2.1 Multidrug-Resistant Tuberculosis 
Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) caused by the 
same mycobacteria organism but molecularly resistant to two of the most potent anti-TB agents, 
rifampicin and isoniazid. Since anti-TB drugs have been used for decades, drug resistance has 
been documented in every country where inappropriate practice of anti-TB treatment is present; 
such as incorrect prescription by healthcare providers, poor quality drugs, and patients’ 
adherence to the treatment (World Health Organization, 2017c). The molecular mechanisms of 
drug-resistant TB depend on different developments such as the genetic basis of resistance, 
mutation rate, mutation type and hetero-resistant and preexisting mutants (Gillespie, 2002), 
which results in different categories of drug resistance including (1) monoresistance – resistant 
only to one first-line anti-TB drug, (2) polydrug resistance – resistant to more than one first-line 
anti-TB drug other than isoniazid and rifampicin, (3) multidrug resistance or MDR-TB – 
resistant to at least both isoniazid and rifampicin, (4) extensive drug resistance or XDR-TB – 
resistant to fluoroquinolone and at least one of injectable drugs in addition to multidrug 
resistance, (5) rifampicin resistance or RR-TB – resistant only to rifampicin with or without 
resistance to other anti-TB drugs (World Health Organization, 2013).  
Treatment of MDR-TB is possible, but only 22% of global MDR-TB/RR-TB patients 
(130,000 of 600,000) received the treatment in 2016 (World Health Organization, 2017c). The 
MDR-TB treatment requires a long duration ranging 9 – 24 months (World Health Organization, 
2016) of expensive antibiotic courses (Kang et al., 2006; Marks et al., 2014; Schnippel et al., 
2013), but they are more toxic and less effective (Micheletti et al., 2016) than the drugs used to 
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treat drug-susceptible TB. In addition, side-effects of MDR-TB treatment affect different 
systems of the human body – ototoxicity, psychiatric disorder, gastrointestinal disturbance, 
arthralgia, hepatitis, epileptic seizures and dermatological complications (Torun et al., 2005; 
Yang et al., 2017). The minor side-effects such as skin reaction, arthralgia, and gastrointestinal 
upsets are common and easily manageable by symptomatic treatment. However, some severe 
toxicities such as nephrotoxicity, cardiotoxicity, gastrointestinal toxicity, central nervous system 
toxicity due to certain drugs are life-threatening (Ramachandran & Swaminathan, 2015). Side-
effects were mostly experienced in 37% to 99% of patients receiving treatment (J. C. Brust et al., 
2013; Yang et al., 2017) that can lead to sporadic treatment interruption, potentially increasing 
the risk of poor treatment outcome (Podewils, Gler, Quelapio, & Chen, 2013).  
 
2.2 Outcome of Multidrug-Resistant Tuberculosis treatment 
The World Health Organization has classified the treatment outcome for RR-TB/MDR-
TB/XDR-TB patients treated using second-line treatment as cured, treatment completed, 
treatment failed, died, lost to follow-up or not evaluated – defining treatment success as the sum 
of cured and treatment completed (World Health Organization, 2013). The median success rate 
of MDR-TB treatment among 23 countries out of 30 high TB burden countries (World Health 
Organization, 2017a) was 53% (IQR 40 – 70%) (Falzon et al., 2015) a rate that is far below the 
target set for Global Plan to stop TB 2011 – 2015 in which the treatment success rate among 
confirmed MDR-TB cases should be ⩾75%.  The overview of adverse outcome among high 
burden countries was 11% (8 – 17) died, 8% (2 – 11) had treatment failure, 13% (8 – 18) were 
lost to follow up, and 4% (1 – 14) were not evaluated (Falzon et al., 2013).  
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There are different factors associated with MDR-TB treatment success such as being 
female, improvement on radiological findings (Jain, Desai, Solanki, & Dikshit, 2014), non-HIV 
patients, sputum smear-negative at baseline, without prior DR-TB (Bastos et al., 2017), use of 
individualized treatment regimen (Kibret, Moges, Memiah, & Biadgilign, 2017) and use of 
fluoroquinolone, aminoglycoside, and Group IV MDR-TB drugs (Anderson et al., 2013; 
Isaakidis et al., 2015). Importantly, adverse treatment outcome is associated with many host-
related factors such as male sex, older age, prior TB treatment (Xu et al., 2018), having HIV co-
infection, low baseline body weight (i.e., < 45 kg) (Farley et al., 2011), chronic viral hepatitis C 
co-infection (Kikvidze & Ikiashvili, 2014), lung cavitation at baseline chest X-ray (Ahmad et al., 
2015), and resistance to ofloxacin and streptomycin (Basit et al., 2014). In addition, higher 
mortality among MDR-TB patient is associated with the used of anti-retroviral therapy (ART) 
before initiation of MDR-TB treatment (Umanah, Ncayiyana, Padanilam, & Nyasulu, 2015), and 
CD4 count ≤100 cells/mm3 (J. C. M. Brust et al., 2018). Therefore, it is important to address the 
determining factors to understand adverse and successful treatment outcomes. 
 
2.3 Hepatitis C  
The first antibody test to HCV became available in 1989 when it was discovered that 
non-A non-B hepatitis was predominantly caused by HCV (H. J. Alter et al., 1989). The World 
Health Organization has defined HCV as a bloodborne virus, commonly transmitted through 
sharing injection materials, reuse and inadequate sterilization of medical equipment, and 
transfusion of unscreened blood (World Health Organization, 2017d). Although the transmission 
of HCV was recognized primarily as blood contact, there are other route of transmission such as 
sexual transmission (Dienstag, 1997), transmission from mother to infant (Ohto et al., 1994), use 
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of folk remedies such as acupuncture and vacuuming (Kiyosawa et al., 1994), and tattoo and 
body piercing (Tohme & Holmberg, 2012). The estimated global prevalence of HCV infection 
was 2.2% (Global Burden Of Hepatitis, 2004), however due to the lack of data from many 
countries, WHO estimated 71 million people have chronic hepatitis C infection, accounting for 
1.34 million deaths in 2015 (World Health Organization, 2017b).  
Acute HCV infection is usually mild and the transition of acute to chronic hepatitis C is 
sub-clinical. Acute HCV infection can be resolved but most frequently progresses to chronic 
hepatitis (Grebely et al., 2014; Yeung, To, King, & Roberts, 2007). Chronic HCV infection is a 
slowly progressing disease with persistent liver inflammation leading to cirrhosis, end-stage liver 
disease and hepatocellular carcinoma (HCC). Globally, chronic HCV contributed to 27% of 
hepatic cirrhosis and 25% of HCC (Perz, Armstrong, Farrington, Hutin, & Bell, 2006). However, 
with the development of direct-acting antiviral (DAA), HCV treatment is more available and 
providing the promising results (Cotte et al., 2016; Sulkowski et al., 2014). Despite these 
advancement, the epidemiological studies on HCV and its interaction on different diseases 
especially patients with HIV and TB are still needed to explore. 
 
2.4 Tuberculosis/ Multidrug-Resistant Tuberculosis and Hepatitis C in HIV population 
Approximately 30% of HIV patients are co-infected with Hepatitis C virus (M. J. Alter, 
2006; Platt et al., 2016) due to shared routes of transmission. With the improvement in HIV 
treatment and increase survival of HIV patient, it has emerged as that the liver complication by 
HCV infection is being a threat to survival of HIV patients. Studies found that HIV infection 
accelerate the liver disease progression in patients co-infected with HCV (Hernandez & 
Sherman, 2011). Tuberculosis is more prevalent in HIV population due to weaken immune 
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system of the host. The pool prevalence of TB/HIV co-infection was 23.51% (95% CI 20.91 – 
26.11) with highest among African countries with 31.25% and lowest in United States with 
14.84% (Gao, Zheng, & Fu, 2013). Medicines used to treat TB have hepatotoxic potential (Yew 
& Leung, 2006). Studies have frequently reported drug-induced hepatotoxicity during TB 
treatment among individuals with HCV co-infection (Kwon et al., 2007; Lomtadze et al., 2013).  
 
2.5 Summary  
The literature review of previous studies highlights –  
 MDR-TB treatment requires the use of second-line drugs for long periods of time, and 
side effects of its treatment are common and serious. 
 Adverse TB treatment outcomes are common among patients with MDR-TB.  
 Knowledge about the impact of HCV infection on MDR TB treatment is lacking, 
especially among patients with HIV. 
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CHAPTER III  
MANUSCRIPT 
Introduction 
Tuberculosis (TB) is one of the top 10 causes of death worldwide. Multidrug-resistant 
tuberculosis (MDR-TB), a form of TB that is resistant to two of the most effective first-line anti-
TB drugs – rifampicin and isoniazid, is a global public health crisis. In 2016, the worldwide 
prevalence of MDR-TB was 4% among new TB cases and 19% among retreatment cases [1]. 
Compared to drug susceptible TB, treatment of MDR-TB is substantially longer (i.e. 9 to 24 
months) [2], requires more expensive and toxic drugs and has a high mortality rate [3, 4]. In 
addition, hepatitis co-infection is a common comorbidity in patients with TB [5], potentially 
increasing the risk of hepatoxicity and mortality during TB treatment [6-8]. For example, 
hepatitis C virus (HCV) causes acute and chronic liver conditions and is associated with adverse 
TB treatment outcomes [9-11]. Given the increased risk of MDR-TB treatment on hepatotoxicity 
[12], HCV co-infection may augment the risk of liver disease during TB treatment leading to 
even greater risk of adverse MDR-TB treatment outcome.  
MDR-TB treatment success rates vary by region, but the median treatment success rate is 
only 53% (IQR 40 – 70%) in high TB burden countries [13-15]. Many patient factors contribute 
to adverse MDR-TB treatment outcomes, but HIV co-infection is of particular concern given its 
link to TB incidence [16] and high mortality during TB treatment [17, 18]. With a potential link 
between HCV and HIV among patients with drug-resistant TB [19], it is important to understand 
the impact of HCV on MDR-TB treatment outcomes in the context of patients with HIV.  
Further epidemiologic data on the role of HCV on adverse MDR-TB outcomes are 
needed to improve treatment guidelines for patients receiving second line anti-TB medicines 
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with multiple risk factors for hepatotoxicity. Improved knowledge regarding the role of HCV on 
adverse MDR-TB treatment outcome in patients with HIV may inform future clinical HIV-TB 
guidelines including side effects monitoring and risk stratification for patients. Mortality due to 
MDR-TB is high even with the proper treatment [3, 4]. Therefore, even incremental 
improvements in MDR-TB treatment outcomes may substantially improve clinical care for high 
HIV/TB burden countries like Myanmar. In this context, we aimed to analyze the association 
between HCV infection and adverse MDR-TB outcome among patients with MDR-TB and HIV. 
 
Methods  
Study design 
We performed a retrospective cohort study using previously collected data from the 
Médecins Sans Frontières (MSF – Doctors without Borders) HIV clinic in Myanmar during 
2009-2017. Participants were registered at the time of TB diagnosis and followed during 
standard MDR-TB and HIV treatment. 
Setting and participants 
In Myanmar, MDR-TB treatment became available in 2009 with a National Tuberculosis 
Program (NTP) and MSF initiated a pilot treatment project in Yangon. Following the pilot, a 
Programmatic Management of Drug-resistant Tuberculosis (PMDT) program was extended in 
2012 to accelerate the MDR-TB treatment program throughout Myanmar.  
Eligible patients for the study included all adults aged ≥18 years receiving HIV treatment 
at MSF Myanmar who had MDR-TB diagnosed by Xpert MTB/RIF test and were confirmed by 
sputum culture and conventional drug sensitivity test (DST).  Solid or liquid sputum culture 
(Lowenstein-Jensen media or Mycobacterium Growth Indicator Tube) were used to confirm 
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Xpert MTB/RIF results and drug resistance patterns.  Patients without a final TB treatment 
outcome or unknown HCV status were excluded.  
Measures and definitions  
The primary outcome of the study was MDR-TB treatment outcome which was defined 
according to WHO categories of cured, treatment completed, treatment failed, died, lost to 
follow-up, and not evaluated [20]. We defined the primary outcome dichotomously as adverse 
(default, failed, died, not evaluated) or favorable (cured, completed).  
The study’s primary exposure was HCV status, classified as positive or negative based on 
OraQuick® hepatitis C antibody test, a point-of-care test used to detect HCV infection. After 
Hepatitis C treatment guideline had implemented in 2015, all HIV patients were routinely tested 
with OraQuick® at the clinic laboratory by laboratory technicians.  
Other covariates of interest included demographic and socioeconomic characteristics 
which were assessed during the clinical consultation. Clinical symptoms of TB, and HIV were 
examined by physicians during clinic visits. Routine laboratory tests such as CD4 count, 
complete blood count, and other tests for MDR-TB side effects such as liver function tests were 
performed in MSF reference laboratories and recorded in the database accordingly. 
Statistical methods 
We used chi-square and Fisher’s exact tests to examine the bivariate association between 
categorical variables and 1) HCV status and 2) adverse MDR-TB outcome. The association 
between both HCV and MDR-TB outcome with continuous variables such as age, BMI, CD4 
count, and laboratory tests were assessed using Wilcoxon rank sum test. Multivariable logistic 
regression models were used to estimate the adjusted association between HCV and MDR-TB 
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treatment outcome. A two-sided p-value <0.05 was considered statistically significant in all 
analyses. SAS 9.4 (Cary, NC) was used to perform all analyses. 
Ethical approval 
Georgia State University and MSF Institutional Review Boards reviewed and approved 
the study’s protocol. 
 
Results 
Participant characteristics  
During the study period, a total of 454 patients registered in the MDR-TB treatment 
program and 387 patients (85%) initiated MDR-TB treatment with second-line drugs. Of these, 
308 (68%) patients had MDR-TB final treatment outcome recorded and 220 with known HCV 
status were included in the analysis (Figure 4.1). Among the 220 patients in our analyses, 8% 
(N=17) were HCV positive, among them the median age was 35 years (IQR 30 – 40) and the 
majority (67%, N=148) were male. 
 
Clinical and laboratory characteristics associated with HCV among MDR-TB patients with HIV 
(Table 3.1) 
Out of 220 patients with HCV test results, the majority of patients had pulmonary TB – 
93% (N=185) in HCV negative group and all 100% (N=17) in HCV positive group (P=0.61). 
Also, most of the cases were retreatment cases: 63% (N=125) among HCV negative and (71% 
(N=12) among HCV positive were previously treated for TB (P=0.52). Regarding HIV clinical 
stage to define the severity of HIV infection, 63% (N=121) were in stage 3 and 37% (N=72) 
were in stage 4 among HCV negative patients, while 59% (N=10) were stage 3 and 41% (N=7) 
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stage 4 in HCV positive group (P=0.75). Almost all patients received HIV treatment – 95% 
(N=193) of HCV negative and 94% (N=16) HCV positive were on treatment for HIV (P=0.60). 
Cotrimoxazole preventive therapy (CPT) prior to MDR-TB treatment initiation was more 
common among HCV negative patients (87%) compared to HCV positive patients (62%) 
(P=0.02). Regarding TB laboratory results, 58% (N=117) of HCV negative patients were sputum 
AFB smear-positive, and 76% (N=13) among HCV positive patients were smear-positive 
(P=0.13). CD4 counts were non-significantly higher in HCV positive patients (median 261 
cells/µL; IQR 148 – 414) compared to HCV negative patients (median 144 cells/µL; IQR 63 – 
274) (P=0.06). Alanine aminotransferase (ALT) levels were not significantly different comparing 
HCV positive patients (median 26.5 IU/L; IQR 22.1 – 31.3) and HCV negative patients (median 
25.6 IU/L; IQR18.1 – 40.85) (P=0.97).  
 
Factors associated with adverse MDR-TB treatment outcome (Table 3.2) 
Among study participants 35% (N=77) had an adverse outcome while 65% (N=143) had 
a favorable treatment outcome. Among patients with pulmonary TB, 34% (68/202) had an 
adverse treatment outcome, and in patients with extrapulmonary, 46% (6/13) had an adverse 
outcome (P=0.38). Regarding previous TB treatment history, 43% (34/79) of new cases and 30% 
(42/137) of retreatment cases had adverse treatment outcomes (P=0.07). HIV clinical stage and 
anti-retroviral therapy provided a difference in MDR-TB treatment outcome. Nearly one-third 
(32%) of patients receiving HIV treatment had adverse outcomes, while the majority (91%) of 
those without HIV treatment had adverse MDR-TB treatment outcomes (P=<0.01).  The 
proportion of patients with cotrimoxazole prophylaxis at enrollment who had adverse outcome 
was non-significantly greater 36% (63/177) compared to those without prophylaxis 29% (9/31) 
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(P=0.48). Regarding TB laboratory results, 32% (41/130) of patients who were sputum smear 
positive had adverse outcome compared to 40% (36/90) with smear negative or non-conclusive 
had an adverse outcome (P=0.20). The median CD4 count was different by treatment outcome: 
among those with adverse outcomes the median CD4 count was 138.5 cells/µL (IQR 64 – 256) 
compared to 173.5 cells/µL (IQR 83 – 365) among those with favorable treatment outcomes 
(P=0.41).  
 
Association between HCV and adverse MDR-TB outcome (Table 3.3) 
In an unadjusted model, the odds of adverse treatment outcome among patients with 
HCV infection was 1.33 (95% CI 0.49 – 3.65) times the odds of those without HCV (Table 3). In 
a model adjusted for age and gender, the odds ratio of adverse treatment outcome comparing 
those with HCV to those without was 1.31 (95% CI 0.47 – 3.61). Additional models adjusted for 
age, gender, and illicit drug use (aOR 1.28 95% CI 0.25 – 6.50) and for previous TB treatment 
history, age, and gender (aOR 1.43 95% CI 0.50 – 4.03) did not substantially change the 
estimated association between HCV and adverse MDR-TB treatment outcome.  
 
Discussion 
This study assessed the relationship between HCV and adverse MDR-TB treatment 
outcomes among patients with HIV co-infection in Myanmar. We observed a high proportion of 
adverse MDR-TB outcomes among patients with HIV—overall more than one-third of patients 
failed, died, or were lost to follow up during second-line TB treatment. We did not detect a 
significant difference in the proportion of patients with and without HCV who had adverse 
outcomes.  
31 
 
The treatment outcome for MDR-TB tuberculosis varies widely among high TB burden 
countries, with a median treatment success rate of 53% and IQR 40 – 70% [13] which is greatly 
lower than the goal of 75% posed by the WHO Global Plan to End TB [21]. In our study, the 
overall treatment success rate was 65%, with 55% cured and 10% completed. Unexpectedly, in 
our patient population, the proportion achieving treatment success among HCV negative patients 
was similar to those with HCV infection. However, the HCV positive group had a slightly lower 
success rate with a considerable proportion (29%) of patients with the outcome not evaluated.  
Although not the objective of our study, we found that HIV treatment at the time of 
registration into the MDR-TB program predicted treatment success. Unlike our findings, 
previous studies of MDR-TB patients with HIV have reported higher mortality among those 
using ART at the time of TB treatment [22], likely due to immune reconstitution inflammatory 
syndrome (IRIS). The majority (62%) of patients with MDR-TB in our study were retreatment 
cases, therefore IRIS was more likely to have occurred during the initial TB disease treatment.  
This study was subject to a number of limitations. First, the study population only 
included half of all registered MDR-TB patients because of incomplete testing for HCV 
antibodies and therefore the study sample size was underpowered to test our hypothesis. 
Moreover, standard testing for HCV began in 2015 after the MDR-TB program had been on-
going. Consequently, a large proportion of patients in our study only had HCV test results 
performed after the initiation of MDR-TB treatment. However, because HCV and HIV may have 
similar modes of transmission [23, 24], it is likely a large proportion of patients were co-infected 
with HCV and HIV at the time of MDR-TB treatment. Third, the quality of data is another 
limitation of the study. Patients’ history, clinical symptoms and medical examination were 
collected by physicians but there were no quality control mechanisms in place to ensure data 
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were complete. Fourth, most of the patient risk factors were self-reported, and therefore several 
behavioral predictors of poor MDR-TB outcome (i.e., smoking, alcohol use, and illicit drug use 
[25-28]) were likely under reported. Liver function tests such as serum bilirubin, alanine amino 
transferase (ALT), aspartate amino transferase (AST) are standard of care [29] in MSF 
Myanmar. However, missing data prohibited the classification of hepatotoxicity in our patients. 
Last, we were unable to differentiate between acute and chronic HCV infection as the point-of-
care test used to measure HCV did not provide HCV RNA confirmation. 
Despite limitations, this is the first study resulting from a pilot MDR-TB treatment 
project at MSF and serves to describe the initial treatment outcomes of MDR-TB patients co-
infected with HIV and HCV in Myanmar. Importantly, as our study used data from the first 
MDR-TB treatment program from Myanmar at the time, patients from several regions were 
included. Therefore, we believe the results of the study are widely generalizable to patients with 
MDR-TB and HIV in the country of Myanmar.  
 
Conclusion  
There is a growing concern that poor MDR-TB treatment outcomes will greatly inhibit 
the EndTB strategy. Our initial findings from Myanmar point to a high rate of MDR-TB 
treatment failure in patients with HIV and suggest that additional work is needed to understand 
the relationship between HCV, hepatotoxicity, and poor TB outcomes among patients with 
MDR-TB and HIV.  
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Table 3.1: Demographic, clinical, and laboratory characteristics of patients with MDR-TB by 
Hepatitis C infection status 
 
Participant 
Characteristics 
Hepatitis C 
Negative 
N= 203 (92%) 
Hepatitis C 
Positive  
N= 17 (8%) 
Total 
N= 220 
P * 
Value 
 
Demographic characteristics  
Age 
   Median (IQR) 
 
35 (30 – 40) 
 
36 (32 – 41) 
 
35 (30 – 40) 
 
0.35 a 
Gender 
   Female 
   Male 
 
69 (34) 
134 (66) 
 
3 (18) 
14 (82) 
 
72 (33) 
148 (67) 
 
0.17 
Marital status 
   Not Disclosed 
   Married  
   Single  
   Divorced  
   Widowed  
   Separated 
 
17 (8) 
102 (50) 
46 (23) 
10 (5) 
20 (10) 
8 (4) 
 
1 (6) 
7 (41) 
5 (29) 
2 (12) 
0 
2 (12) 
 
18 (8) 
109 (50) 
51 (23) 
12 (5) 
20 (9) 
10 (5) 
 
0.23 b 
Employment 
   Not Disclosed 
   Employed 
   Pensioner 
   Student  
   Unemployed 
   Housework 
   Others 
 
44 (22) 
50 (25) 
0 
0 
86 (42) 
8 (4) 
15 (7) 
 
1 (6) 
4 (24) 
0  
0 
8 (47) 
0 
4 (24) 
 
45 (20) 
54 (24) 
0 
0 
94 (43) 
8 (4) 
19 (9) 
 
0.15 b 
Risk Factors 
 
Prison  
   Not been in Prison 
   Ever been in Prison 
 
 
 
195 (96) 
8 (4) 
 
 
 
16 (94) 
1 (6) 
 
 
 
211 (96) 
9 (4) 
 
 
 
0.70 
 
Alcohol use 
   No 
   Yes 
   Missing 
 
 
190 (96) 
8 (4) 
5 
 
 
16 (94) 
1 (6) 
0 
 
 
206 (94) 
9 (4) 
5 (2) 
 
 
0.53 b 
 
Illicit Drug use 
   No 
   Yes 
   Missing  
 
 
81 (40) 
0 
122 (60) 
 
 
7 (41) 
2 (12) 
8 (47) 
 
 
88 (40) 
2 (1) 
130 (59) 
 
 
< 0.01 b c 
 
Tobacco use 
   No 
   Yes 
 
 
190 (94) 
13 (6) 
 
 
15 (88) 
2 (12) 
 
 
205 (93) 
15 (7) 
 
 
0.33 b 
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Participant 
Characteristics 
Hepatitis C 
Negative 
N= 203 (92%) 
Hepatitis C 
Positive  
N= 17 (8%) 
Total 
N= 220 
P * 
Value 
 
 
Homeless 
   No 
   Yes 
 
 
201 (99) 
2 (1) 
 
 
17 
0 
 
 
218 (99) 
2 (1) 
 
 
1.00 b 
 
Migrant 
   No 
   Yes 
 
 
202 (99) 
1 (1) 
 
 
17  
0 
 
 
219 (99) 
1 (1) 
 
 
1.00 b 
 
Prostitution 
   No 
   Yes 
 
 
 
200 (99) 
3 (1) 
 
 
17 
0 
 
 
217 (99) 
3 (1) 
 
 
1.00 b 
Clinical characteristics 
Site of TB 
   Pulmonary 
   Extra-pulmonary 
   Missing  
 
185 (93) 
13 (7) 
5 
 
17 
0 
 
202 (92) 
13 (6) 
5 (2) 
 
0.61 b 
TB treatment history 
   New Case 
   Failure 
   Relapse  
   Treatment 
interrupted 
   Unknown 
 
74 (37) 
47 (23) 
71 (35) 
5 (2) 
2 (1) 
4 (2) 
 
5 (29) 
6 (35)  
6 (35) 
0 
0 
 
79 (36) 
53 (24) 
77 (35) 
5 (2) 
2 (1) 
4 (2) 
 
0.75 b 
Previous TB history 
   New Case 
   Retreatment Case 
   Missing  
 
74 (36) 
125 (62) 
4 (2) 
 
5 (29) 
12 (71) 
0 
 
79 (36) 
137 (62) 
4 (2) 
 
0.52 
HIV clinical stage 
   Stage 3 
   Stage 4 
   Missing 
 
121 (63) 
72 (37) 
10 
 
10 (59) 
7 (41) 
0 
 
131 (60) 
79 (39) 
10 (5) 
 
0.75 
HIV treatment 
   No 
   Yes 
 
10 (5) 
193 (95) 
 
1 (6) 
16 (94) 
 
11 (5) 
209 (95) 
 
0.60 b 
Cotrimoxazole 
prophylaxis at 
enrollment 
   No 
   Yes 
   Missing 
 
 
 
25 (12) 
167 (82) 
11 (6) 
 
 
 
6 (38) 
10 (62) 
1 
 
 
 
31 (14) 
177 (80) 
12 (6) 
 
 
 
0.02 b 
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Participant 
Characteristics 
Hepatitis C 
Negative 
N= 203 (92%) 
Hepatitis C 
Positive  
N= 17 (8%) 
Total 
N= 220 
P * 
Value 
 
BMI 
   Median (IQR) 
   (N = 186) 
 
17.1 (15.5 – 
18.6)  
 
16.65 (14.05 – 
18) 
 
17.05 (15.4 – 
18.6)  
 
0.24 a 
Clinical Symptoms 
    
Fever 
     No 
     Yes 
  
  Sweat 
     No 
     Yes 
   
  Dry cough 
     No 
     Yes 
 
  Productive cough 
     No 
     Yes 
  
  Blood spitting 
     No 
     Yes 
  
  Chest Pain 
      No 
      Yes 
   
   Loss of Appetite 
      No 
      Yes 
   
  Weight Loss 
      No 
      Yes 
   
   Dyspnea 
      No 
      Yes 
 
 
 
 
 
 
113 (56) 
90 (44) 
 
 
162 (80) 
41 (20) 
 
 
180 (89) 
23 (11) 
 
 
121 (60) 
82 (40) 
 
 
197 (97) 
6 (3) 
 
 
172 (85) 
31 (15) 
 
 
126 (62) 
77 (38) 
 
 
126 (62) 
77 (38) 
 
 
149 (73) 
54 (27) 
 
 
 
 
12 (71) 
5 (29) 
 
 
16 (94) 
1 (6) 
 
 
15 (88) 
2 (12) 
 
 
9 (53) 
8 (47) 
 
 
17 
0 
 
 
16 (94) 
1 (6) 
 
 
11 (65) 
6 (35) 
 
 
11 (65) 
6 (35) 
 
 
14 (82) 
3 (18) 
 
 
 
125 (57) 
95 (43) 
 
 
178 (81) 
42 (19) 
 
 
195 (87) 
25 (13) 
 
 
130 (59) 
90 (41) 
 
 
214 (97) 
6 (3) 
 
 
188 (85) 
32 (15) 
 
 
137 (62) 
83 (38) 
 
 
137 (62) 
83 (38) 
 
 
163 (74) 
57 (26) 
 
 
 
0.23 
 
 
 
0.21 b 
 
 
 
1.00 b 
 
 
 
0.59 
 
 
 
1.00 b 
 
 
 
0.48 b 
 
 
 
0.83 
 
 
 
0.83 
 
 
 
0.57 b 
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Participant 
Characteristics 
Hepatitis C 
Negative 
N= 203 (92%) 
Hepatitis C 
Positive  
N= 17 (8%) 
Total 
N= 220 
P * 
Value 
 
Laboratory characteristics 
Sputum smear result  
   Not conclusive 
   Negative 
   Positive 
   Missing  
 
6 (3) 
68 (36) 
117 (61) 
12 
 
0 
4 (24) 
13 (76) 
0 
 
6 (3) 
72 (33) 
130 (59) 
12 (5) 
 
0.41 
Sputum smear result  
   Negative & non-
conclusive 
   Positive 
 
86 (42) 
 
117 (58) 
 
4 (24) 
 
13 (76) 
 
90 (41) 
 
130 (59) 
 
0.13 
CD4 count (cells/µL) 
   Median (IQR) 
   (N = 120) 
 
144 (63 – 274) 
 
261 (148 – 414)  
 
161 (73 – 296) 
 
0.06 a 
ALT (IU/L) 
   Median (IQR) 
   (N = 93) 
 
25.6 (18.1 – 
40.85)  
 
26.5 (22.1 – 
31.3) 
 
26 (18.2 – 40.4) 
 
0.97 a 
Primary outcome variable 
MDR-TB Treatment 
outcome ^ 
   Completed 
   Cured 
   Defaulter 
   Died 
   Failure 
   Not evaluated   
 
 
20 (10) 
113 (55) 
22 (11) 
30 (15) 
2 (1) 
16 (8) 
 
 
1 (6) 
9 (53) 
0 
1 (6) 
1 (6) 
5 (29) 
 
 
21 (10) 
122 (55) 
22 (10) 
31 (14) 
3 (1) 
21 (10) 
 
 
0.03 b 
MDRTB Treatment 
outcome 
   Favorable  
   Adverse 
 
 
133 (66) 
70 (34) 
 
 
10 (59) 
7 (41) 
 
 
143 (65) 
77 (35) 
 
 
0.58 
Abbreviation: IQR – interquartile range, BMI – Body Mass Index, ALT – alanine 
aminotransferase, MDRTB – Multidrug-resistant Tuberculosis 
* chi-square test with 2-sided probability 
a Wilcoxon Scores (Rank Sums) 
b Fisher's Exact Test 
c included the missing values  
^ WHO definition framework for TB treatment outcome  
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Table 3.2: Factors associated with MDR-TB treatment outcome and HCV infection, univariate 
analysis 
 
Participant 
Characteristics 
Adverse 
Treatment 
outcome  
N= 77 (35%) 
Favorable 
Treatment 
Outcome  
N= 143 (65%) 
Total 
N= 220 
P value * 
Primary exposure variable 
Hepatitis C Negative 
Hepatitis C Positive 
70 (34) 
7 (41) 
133 (66) 
10 (59) 
203 (92) 
17 (8) 
0.58 
Demographic Characteristics  
Age, years 
   Median (IQR) 
 
35 (31 – 41) 
 
35 (30 – 40) 
 
35 (30 – 40) 
 
0.96 a 
Gender 
   Female 
   Male 
 
24 (33) 
53 (36) 
 
48 (67) 
95 (64) 
 
72 (33) 
148 (67) 
 
0.72 
Marital status 
   Not Disclosed 
   Married  
   Single  
   Divorced  
   Widowed  
   Separated 
 
9 (50) 
33 (30) 
21 (41) 
3 (25) 
5 (25) 
6 (60) 
 
9 (50) 
76 (70) 
30 (59) 
9 (75) 
15 (75) 
4 (40) 
 
18 (8) 
109 (50) 
51 (23) 
12 (5) 
20 (9) 
10 (5) 
 
0.16 
Employment 
   Not Disclosed 
   Employed 
   Pensioner 
   Student  
   Unemployed 
   Housework 
   Others 
 
18 (40) 
22 (41) 
 
 
26 (28) 
4 (50) 
7 (37) 
 
27 (60) 
32 (59) 
 
 
68 (72) 
4 (50) 
12 (63) 
 
45 (20) 
54 (25) 
0 
0 
94 (43) 
8 (4) 
19 (9) 
 
0.36 
Risk Factors 
 
Prison risk factor 
   Not been in Prison 
   Ever been in Prison 
 
 
 
75 (36) 
2 (22) 
 
 
 
136 (64) 
7 (78) 
 
 
 
211 (96) 
9 (4) 
 
 
 
0.50 b 
 
Alcohol use 
   No 
   Yes 
   Missing 
 
 
73 (35) 
3 (33) 
1 
 
 
133 (65) 
6 (67) 
4 
 
 
206 (94) 
9 (4) 
5 (2) 
 
 
1.00 b 
 
Illicit Drug use 
   No 
   Yes 
   Missing  
 
 
31 (35) 
1 (50) 
45 (35) 
 
 
57 (65) 
1 (50) 
85 (65) 
 
 
88 (40) 
2 (1) 
130 (59) 
 
 
1.00 b 
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Participant 
Characteristics 
Adverse 
Treatment 
outcome  
N= 77 (35%) 
Favorable 
Treatment 
Outcome  
N= 143 (65%) 
Total 
N= 220 
P value * 
 
Tobacco use 
   No 
   Yes 
 
 
72 (35) 
5 (33) 
 
 
133 (65) 
10 (67) 
 
 
205 (93) 
15 (7) 
 
 
0.89 
 
Homeless 
   No 
   Yes 
 
 
77 (35) 
0 
 
 
141 (65) 
2 (100) 
 
 
218 (99) 
2 (1) 
 
 
0.54 b 
 
Migrant 
   No 
   Yes 
 
 
76 (35) 
1 (100) 
 
 
143 (65) 
0 
 
 
219 (99) 
1 (1) 
 
 
0.35 b 
 
Prostitution 
   No 
   Yes 
 
 
75 (35) 
2 (67) 
 
 
142 (65) 
1 (33) 
 
 
217 (99) 
3 (1) 
 
 
0.28 b 
Clinical Characteristics 
Site of TB 
   Extra-Pulmonary 
   Pulmonary 
   Missing  
 
6 (46) 
68 (34) 
3 
 
7 (54) 
134 (66) 
2 
 
13 (6) 
202 (92) 
5 (2) 
 
0.38 b 
Previous TB 
treatment 
   New Case 
   Failure 
   Relapse  
   Treatment 
interrupted 
   Unknown 
 
34 (43) 
15 (28) 
24 (31) 
2 (40) 
1 (50) 
1 
 
45 (57) 
38 (72) 
53 (69) 
3 (60) 
1 (50) 
3 
 
79 (36) 
53 (24) 
77 (35) 
5 (2) 
2 (1) 
4 (2) 
 
0.34 b 
Previous TB 
treatment 
   New Case 
   Retreatment Case 
 
34 (43) 
42 (30) 
1 
 
45 (57) 
95 (70) 
3 
 
79 (36) 
137 (62) 
4 (2) 
 
0.07 
HIV clinical stage 
   Stage 3 
   Stage 4 
   Missing 
 
47 (36) 
24 (30) 
6 
 
84 (64) 
55 (70) 
4 
 
131 (60) 
79 (36) 
10 (4) 
 
0.41 
HIV treatment 
   No 
   Yes 
 
10 (91) 
67 (32) 
 
1 (9) 
142 (68) 
 
11 (5) 
209 (95) 
 
< 0.01 b 
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Participant 
Characteristics 
Adverse 
Treatment 
outcome  
N= 77 (35%) 
Favorable 
Treatment 
Outcome  
N= 143 (65%) 
Total 
N= 220 
P value * 
Cotrimoxazole 
prophylaxis at 
enrollment 
   No 
   Yes 
   Missing 
 
 
 
9 (29) 
63 (36) 
5 
 
 
 
22 (71) 
114 (64) 
7 
 
 
 
31 (14) 
177 (80) 
12 (6) 
 
 
 
0.48 
BMI 
   Median (IQR) 
   (N = 186) 
 
17.1 (15.6 – 18.8) 
 
17 (15.4 – 18.5) 
 
17.05 (15.4 – 
18.6)  
 
0.77 a 
Clinical Symptoms 
    
Fever 
     No 
     Yes 
  
  Sweat 
     No 
     Yes 
   
  Dry cough 
     No 
     Yes 
 
  Productive cough 
     No 
     Yes 
  
  Blood spitting 
     No 
     Yes 
  
  Chest Pain 
      No 
      Yes 
   
   Loss of Appetite 
      No 
      Yes 
   
  Weight Loss 
      No 
      Yes 
 
 
 
40 (32) 
37 (39) 
 
 
58 (33) 
19 (45) 
 
 
68 (35) 
9 (36) 
 
 
50 (38) 
27 (30) 
 
 
73 (34) 
4 (67) 
 
 
66 (35) 
11 (34) 
 
 
51 (37) 
26 (31) 
 
 
50 (37) 
27 (33) 
 
 
 
85 (68) 
58 (61) 
 
 
120 (67) 
23 (55) 
 
 
127 (65) 
16 (64) 
 
 
80 (62) 
63 (70) 
 
 
141 (64) 
2 (33) 
 
 
122 (65) 
21 (66) 
 
 
86 (63) 
57 (69) 
 
 
87 (63) 
56 (67) 
 
 
 
125 (57) 
95 (43) 
 
 
178 (81) 
42 (19) 
 
 
195 (87) 
25 (13) 
 
 
130 (59) 
90 (41) 
 
 
214 (97) 
6 (3) 
 
 
188 (85) 
32 (15) 
 
 
137 (62) 
83 (38) 
 
 
137 (62) 
83 (83) 
 
 
 
0.28 
 
 
 
0.12 
 
 
 
0.91 
 
 
 
0.20 
 
 
 
0.19 b 
 
 
 
0.94 
 
 
 
0.37 
 
 
 
0.55 
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Participant 
Characteristics 
Adverse 
Treatment 
outcome  
N= 77 (35%) 
Favorable 
Treatment 
Outcome  
N= 143 (65%) 
Total 
N= 220 
P value * 
   
   Dyspnea 
      No 
      Yes 
 
 
 
62 (38) 
15 (26) 
 
 
101 (62) 
42 (74) 
 
 
163 (74) 
57 (26) 
 
 
0.11 
Laboratory Characteristics  
Smear result  
   Not conclusive 
   Negative 
   Positive 
   Missing 
 
1 (17) 
28 (39) 
41 (32) 
7 
 
5 (83) 
44 (61) 
89 (68) 
5 
 
6 (3) 
72 (33) 
130 (59) 
12 (5) 
 
0.42 b 
Smear result  
   Negative & non-
conclusive 
   Positive 
 
36 (40) 
 
41 (32) 
 
54 (60) 
 
89 (68) 
 
90 (41) 
 
130 (59) 
 
0.20 
 
CD4 count (cells/µL) 
   Median (IQR) 
   (N = 120) 
 
138.5 (64 – 256) 
 
173.5 (83 – 365) 
 
161 (73 – 296) 
 
0.41 a 
ALT (IU/L) 
   Median (IQR) 
   (N = 93) 
 
21.3 (18.2 – 30.8) 
 
28 (18.5 – 42.55) 
 
26 (18.2 – 40.4) 
 
0.20 a 
Abbreviation: IQR – interquartile range, BMI – Body Mass Index, ALT – alanine 
aminotransferase, MDRTB – Multidrug-resistant Tuberculosis 
* chi-square test with 2-sided probability 
a Wilcoxon Scores (Rank Sums) 
b Fisher's Exact Test 
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Table 3.3: Association between HCV and adverse MDR-TB treatment outcomes, multivariate 
analysis (N=220) 
 
Participant 
Characteristics 
Adverse 
Treatment 
Crude OR 
(95%CI) 
 
Model 1 
Adjusted OR 
(95%CI) 
 
Model 2 
Adjusted OR 
(95%CI) 
 
Model 3 
Adjusted OR 
(95%CI) 
Hepatitis C 
   Negative 
   Positive 
 
1 
1.33 (0.49 – 3.65) 
 
1 
1.31 (0.47 – 3.61) 
 
1 
1.43 (0.50 – 4.03) 
 
1 
1.28 (0.25 – 6.50) 
Model 1 adjusted for age and gender 
Model 2 adjusted for age, gender, smear result, and history of previous TB treatment 
Model 3 adjusted for age, gender, and illicit drug use 
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Figure 4.1 Participant selection of the study 
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